What Wall Street expects from Kyverna Therapeutics KYTX this quarter KYTX Q4 2025 Kyverna Therapeutics Beats EPS Estimates with Zero Revenue OEC Orion SA posts Q1 2026 loss against profit estimates shares dip 132 today APO Apollo posts 193 percent Q4 2025 EPS beat even as shares dip 104 percent in todays trading Vertex Pharmaceuticals VRTX Poised for Material Upside as Lead IgA Nephropathy Asset Rides FastExpanding Rare Kidney Disease Market CSGP CoStar shares climb 267 as quarterly earnings beat estimates by 225 on strong revenue growth REGCP Regency delivers 153 percent Q4 2025 EPS surprise shares rise 104 percent on strong quarterly results Why ParaZero Technologies PRZO deserves more attention from serious investors Mini Selloff 20260506 NSC Norfolk posts 45 percent Q1 2026 EPS beat yet shares fall 145 percent in todays trading